Background
==========

HIV and malignancies
--------------------

Historically, HIV infection is associated with a much higher risk of specific cancers \[[@B1]-[@B4]\]. In particular, diagnosis of Kaposi sarcoma, non-Hodgkin lymphoma (NHL), or cervical cancer are considered acquired immunodeficiency syndrome (AIDS)-defining malignancies \[[@B5]\]. However, increasing effectiveness of anti-retroviral therapy (ART) has led to decreased mortality in Europe and North America from opportunistic infections and AIDS-defining malignancies \[[@B5]-[@B8]\], while mortality from non-AIDS-defining and non-HIV-associated cancers has been increasing \[[@B8],[@B9]\].

Response to cancer therapy is also different in the HIV patient population. Initial reports found increased radiotoxicity in HIV patients receiving treatment for Kaposi sarcoma, cervical carcinoma, while there was no difference in adverse effects of radiation therapy for other malignancies \[[@B10],[@B11]\]. Systemic glutathione deficiency \[[@B12]\], DNA repair deficiency, or cell cycle dysregulation may increase radiosensitivity \[[@B13]-[@B15]\]. However, radiation therapy remains a cornerstone of therapy in a number of cancers such as anal cancer \[[@B16]\], prostate \[[@B17]\], breast \[[@B18]-[@B20]\], and cervical cancer \[[@B16],[@B21]\].

Protease inhibitors in the treatment of HIV
-------------------------------------------

PIs are anti-viral drugs that inhibit proteases, viral enzymes which cleave polyprotein precursors into mature viral proteins \[[@B22]\]. PIs are one class of anti-virals that is used as the \'base\' in combination with two \'backbone\' drugs for treatment of HIV, antiretroviral therapy (ART). There are currently ten PIs available; in chronological order of FDA approval, saquinavir, ritonavir, indinavir, nelfinavir, lopinavir, atazanavir, fosamprenavir (pro-drug of amprenavir, which is no longer available), tipranavir, and darunavir.

Although PIs act by inhibiting HIV aspartyl protease, they also have off-target effects. The entire class is associated with dysregulation of glucose and lipid metabolism due to homology between HIV-1 protease and various human proteins \[[@B23]-[@B26]\]. In addition, some PIs inhibit the phosphatidyl-inositol 3-kinase (PI3K)-Akt pathway, which is shared by numerous cell homeostasis pathways \[[@B27],[@B28]\].

Non-target effects of protease inhibitors
-----------------------------------------

A number of PIs have been associated with anti-cancer activity \[[@B29]\]. Through PI3K-Akt and closely related pathways, PIs induce apoptosis of tumor cells \[[@B30]-[@B36]\]. Although PIs have been shown to directly effect tumor cell death, use of PIs has not reduced cancer risk in HIV patients, suggesting that PIs would not be clinically effective anti-cancer monotherapies \[[@B37]\]. Although ineffective alone, PIs synergize with other cancer therapies such as radiotherapy \[[@B38]\].

Initial studies suggested that nelfinavir upregulates vascular endothelial growth factor (VEGF) and downregulates hypoxia-inducible factor 1 alpha (HIF-1α). Although VEGF can increase tumor oxygenation, the HIF1-α hypoxia factor can mediate radiation resistance \[[@B39],[@B40]\]. However, HIF-1α knockdown studies suggest that radiosensitivity induced by PIs is independent of HIF-1α \[[@B28],[@B40]-[@B42]\]. In a number of cancers, resistance to radiotherapy is mediated by the PI3K-Akt pathway, suggesting an alternative mechanism of PI-induced radiosensitization \[[@B43]-[@B45]\]. Preclinical studies with nelfinavir in head-and-neck cancer \[[@B46]\] and non-small cell lung cancer \[[@B28]\] cell lines found downregulation of Akt to be associated with increased sensitivity to radiation.

Although PI-induced radiosensitization of cancers was shown to be independent of HIF-1α, PIs have been shown to induce systemic vascular stress \[[@B47]\]. Preclinical *in vivo*studies suggest that in addition to direct effect on the tumor cells, PIs may inhibit PI3K-Akt activation in tumor vasculature, suppressing hypoxia pathways and leading to reduced radiation resistance \[[@B48],[@B49]\]. Other clinical reports also suggest that PIs and radiotherapy interact on tumor vasculature similar to the effects of radiation and bevacizumab, an anti-angiogenic antibody \[[@B50]\].

Protease inhibitors and radiotherapy
------------------------------------

A retrospective review (14 patients receiving PIs and 28 controls) did not find severe toxicities attributable to combination of PIs and radiotherapy for cancer in HIV+ patients \[[@B11],[@B51]-[@B54]\]. There are ten prospective trials, nine of which are on-going (a phase II trial was terminated due to poor enrollment): five phase I studies, and four studies that have a phase II component. One published phase I trial in pancreatic cancer showed the following toxicites one of which was life-threatening: severe nausea and vomiting and increase in liver enzymes and bilirubin due to stent occlusion \[[@B55]\]. Given the inconclusive safety data on combining PIs and radiation therapy to treat cancer in HIV patients, we reviewed a series of HIV patients receiving radiation therapy for malignancies.

Methods
=======

Patient identification
----------------------

In accordance with a research protocol approved by the Institutional Review Board, patients were identified by review of clinical records from January 1, 2009-October 31, 2010 in the Department of Radiation Oncology at The Johns Hopkins Hospital. Patients were included if they had documented HIV infection and received radiation therapy at Johns Hopkins.

Retrospective review
--------------------

Medical records for included patients were reviewed for HIV medications, cancer diagnosis and stage, radiation therapy (site, dose, fractionation, completion or early stopping), age at time of radiation therapy, cancer chemotherapy, acute (\< 6 weeks after end of radiation therapy) toxicities categorized by Common Toxicity Criteria for Adverse Events version 3.0 (CTCAE) grade. All patients receiving radiation therapy were evaluated at least once per week for treatment toxicity, and side effects were recorded prospectively in an electronic record system.

Statistical analysis
--------------------

Patients were categorized by type of malignancy (AIDS-defining, HIV-associated, non-HIV associated), taking non-PI HIV medications (yes/no), and by baseline CD4 count (\< 50, \<200, \<500, 500). Toxicities were categorized by CTCAE grade. Differences between the groups were analyzed using Pearson\'s chi-square test with JMP 8.0 (SAS Institute Inc.). Statistical significance was defined as a Pearson\'s chi-square p-value \< 0.05.

Results
=======

We retrospectively reviewed acute toxicities in a series of patients with a history of HIV infection and receiving radiation therapy; in this series, we compared patients who received concurrent PIs with patients who did not receive concurrent PIs. Eighteen patients received concurrent PIs and radiation therapy; one patient received radiation therapy for two different malignancies, and one patient received radiation for three recurrences of NHL. There were eleven patients with a history of HIV infection but not treated with PIs who received radiation therapy; one patient received three regimens of radiation therapy, twice for brain metastasis and once for testicular metastasis.

Patient characteristics
-----------------------

Characteristics of patients receiving concurrent protease inhibitor are presented in Table [1](#T1){ref-type="table"} while characteristics of patients not receiving concurrent protease inhibitor are presented in Table [2](#T2){ref-type="table"}. There were 34 total courses of radiation treatment delivered (21 with PIs, 13 without PIs) for a variety of histologies, including HIV-defining (0 with PIs; 3 \[23%\] without PIs), HIV-associated (11 \[58%\] with PIs; 5 \[38%\] without PIs), non-HIV-associated malignancies (8 \[42%\] with PIs, 5 \[38%\] without PIs), and non-malignancies (keloid scar and dural arteriovenous fistula with PIs, none without PIs). The median age was 50 (interquartile range \[IQR\] 47-56). The difference between the two groups in number of AIDS-defining malignancies almost reached statistical significance (p = 0.06), but the remainder of the malignancies (HIV-associated and non-HIV-associated) are not differently distributed in the two groups (p = 0.9). 29 cases had documented pre-treatment CD4 counts; 4 were \<50 (4 \[24%\] with PIs), 13 were \<200 (9 \[53%\] with PIs, 4 \[33%\] without PIs), and 21 were \<500 (10 \[59%\] with PIs; 11\[92%\] without PIs). Patients taking PIs were more likely than patients not taking PIs to have a CD4 count≥500 (7 \[41%\] with PIs; 1 \[8%\] without PIs; p-0.006).

###### 

Baseline data: patients receiving concurrent protease inhibitor

  \#    Cancer diagnosis                                                 Age   Concurrent systemic therapy   Baseline CD4   Non-PI HIV regimen                      PI
  ----- ---------------------------------------------------------------- ----- ----------------------------- -------------- --------------------------------------- ----------
  1a    Ductal carcinoma, breast T2N1M0                                  47    None                          104            lamivudine, raltegravir                 RTV, DRV
  1b    SCC, anus T3N0M0                                                 49    5-FU, mitomycin C             68             lamivudine, raltegravir                 RTV, DRV
  2     SCC, vulva T1bN1b, stage IIIa                                    26    cisplatin                     1647           emtricitabine, tenofovir                RTV, ATZ
  3     Ductal carcinoma, breast T1cN0M0, stage I                        47    None                          474            emtricitabine, tenofovir, raltegravir   RTV, ATZ
  4     SCC, anus T2N0M0, stage II                                       47    None                          NR             emtricitabine, tenofovir, raltegravir   RTV, DRV
  5     Adenocarcinoma, prostate cT2bNXM0, GS 3+3, PSA 8.7, stage II     58    None                          WNL            efavirenz, emtricitabine, tenofovir     RTV, LPV
  6     Adenocarcinoma, prostate cT1cNXM0, GS 3+4, PSA 4.9, stage II     73    androgen deprivation          1105           raltegravir                             RTV, DRV
  7     Adenocarcinoma, prostate cT1cNXM0, GS 4+3, PSA 5.1stage II       69    androgen deprivation          536            abacavir, lamivudine                    RTV, ATZ
  8     Renal cell carcinoma, lateral chest wall, metastatic, stage IV   50    sutent                        766            emtricitabine, tenofovir, efavirenz     RTV, ATZ
  9     Arteriovenous fistula, dura mater                                57    None                          944            abacavir, lamivudine, raltegravir       RTV, LPV
  10    SCC, tonsil T2N2bM0                                              53    cisplatin                     956            emtricitabine, tenofovir                RTV, LPV
  11    Primary CNS lymphoma, CNS                                        44    None                          4              None                                    RTV, DRV
                                                                               doxil, cytoxan,                                                                      
  12    NHL, neck and axilla, stage IV                                   53    vincristine, prednisone       57             abacavir, lamivudine                    RTV
  13a   NHL, pelvis, stage IV                                            53    None                          120            abacavir, lamivudine                    RTV, ATZ
  13b   NHL, axilla, stage IV                                            55    None                          39             abacavir, lamivudine                    RTV, LPV
  13c   NHL, temple, stage IV                                            56    None                          87             abacavir, lamivudine                    RTV, LPV
  14    Primary CNS lymphoma, CNS                                        21    None                          0              emtricitabine, tenofovir                RTV, DRV
  15    Ductal carcinoma, breast T2N0M0, stage IIa                       58    None                          NR             emtricitabine, tenofovir                RTV, LPV
  16    SCC, anus T1N0M0, stage I                                        43    5-FU, mitomycin C             547            abacavir, lamivudine                    RTV, LPV
  17    Primary CNS lymphoma, CNS                                        23    None                          10             emtricitabine, tenofovir                RTV, DRV
  18    Keloid scar, posterior scalp                                     47    None                          WNL            zidovudine 300 mg, lamivudine 150 mg    NFV

Patients are uniquely identified by numbers, repeated treatments on a patient are distinguished by a letter after the number.

NHL = non-Hodgkin lymphoma

cT = clinical tumor, pT = pathological tumor, GS = Gleason score, PSA = prostate specific antigen

RTV = ritonavir, DRV = darunavir, ATZ = atazanavir, LPV = lopinavir, NFV = nelfinavir

WNL = Reported as within normal limits, NR = not reported

###### 

Baseline data: patients not receiving concurrent protease inhibitor

  ------------------------------------------------------------------------------------------------------------------------------
  \#   Cancer diagnosis                            Age   Concurrent\        Baseline\   Non-PI HIV regimen                    
                                                         systemic therapy   CD4                                               
  ---- ------------------------------------------- ----- ------------------ ----------- ------------------------------------- --
  1    SCC, cervix T4N1M0, stage IVa               29    cisplatin          189         None                                  

  2    SCC, cervix, stage IIb                      34    cisplatin          189         None                                  

  3    Cholangiocarcinoma, abdomen pT3N1M0         53    xeloda             300         efavirenz, emtricitabine, tenofovir   

  4    Adenocarcinoma, prostate TXNXM1, stage IV   48    None               399         None                                  

  5    Meningioma, CNS                             46    None               408         None                                  

  6    Adenocarcinoma, prostate cT1cNXM0, GS       62    androgen           1047        None                                  

       3+4, PSA 20.6, stage II                           deprivation                                                          

  7    NSCLC, brain met, stage IV                  57    None               NR          None                                  

  8a   DLBCL, brain met, stage IV                  46    None               214         efavirenz, emtricitabine, tenofovir   

  8b   DLBCL, brain met recurrence, stage IV       46    None               214         efavirenz, emtricitabine, tenofovir   

  8c   DLBCL, testicular met, stage IV             46    None               214         efavirenz, emtricitabine, tenofovir   

  9    Adenocarcinoma, prostate cT2aNXM0, GS       61    None               150         efavirenz, emtricitabine, tenofovir   

       3+4, PSA 1.1, stage II                                                                                                 

  10   SCC, cervix, stage IIIb                     57    cisplatin          116         None                                  

  11   SCC, anal                                   49    mitomycin C and\   450         efavirenz, emtricitabine, tenofovir   
                                                         xeloda                                                               
  ------------------------------------------------------------------------------------------------------------------------------

Patients are uniquely identified by numbers, repeated treatments on a patient are distinguished by a letter after the number.

NHL = non-Hodgkin lymphoma, DLBCL = diffuse large B-cell lymphoma

cT = clinical tumor, pT = pathological tumor, GS = Gleason score, PSA = prostate specific antigen

NR = not reported

Radiation treatment
-------------------

For the 29 patients receiving radiation therapy, 15 patients were treated with definitive or adjuvant dose regimens (9 receiving PIs, 6 without PIs), while 14 patients received palliative radiation doses (9 receiving PIs, 5 without PIs). The exact definition of definitive/adjuvant versus palliative dose varied based on body site. Definitive/adjuvant dose was at least 5400 cGy for brain (conventional fractionation equivalent), 7000 cGy for head and neck, 5400 cGy for breast, 4500 cGy for pelvis, and 7800 cGy for prostate. Palliative doses also varied based on body site and disease histology, but were lower than definitive/adjuvant dose regimens.

HIV medications and systemic chemotherapy
-----------------------------------------

Systemic chemotherapy regimens for these two groups of patients are presented (Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Of the 32 treatments for cancer (19 with PIs, 13 without PIs), 13 included systemic chemotherapy regimens (7 \[37%\] with PIs; 6 \[46%\] without PIs). 21 of the 29 patients were receiving HIV medications (17 \[94%\] with PIs; 4 \[36%\] without PIs; p = 0.001).

In the group receiving PIs, the most common PI was ritonavir (20 \[95%\]), followed by darunavir and lopinavir (7 \[33%\] each), atazanavir (5 \[24%\]), and only one \[5%\] patient received nelfinavir (Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

Toxicities
----------

Follow-up and observed toxicities are presented in Table [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}. The median follow-up of all patients was 18 weeks \[IQR 8-30\], but the follow-up for patients not taking PIs (median 13 weeks \[IQR 5-18\]) was much shorter than the follow-up for patients taking PIs (median 21 weeks \[IQR 10-38\]). The limited follow-up in the group not taking PIs prevented comparison of long-term toxicities.

###### 

Radiation regimen, follow-up and toxicities in patients receiving concurrent protease inhibitor

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#    F/U\        Region treated                              Dose (fractionation)\   Complete RT regimen   Acute toxicity and CTC grade
        \[weeks\]                                               \[cgy\]                                       
  ----- ----------- ------------------------------------------- ----------------------- --------------------- --------------------------------------------------------------------------------------
  1a    75          right breast                                5800 (200)              yes                   dermatitis 2, pruritis 1, hyperpigmentation 2, fatigue 1, pain 1

  1b    0           pelvis                                      3600 (180)              no, prescribed 5400   fatigue 2, pain 2, nocturia 2, anorexia 1, proctitis 2

                                                                                                              fatigue 1, pain 1, nocturia and urinary

  2     9           pelvis and left vulva                       4500 (180)              yes                   frequency 1, dysuria 2, proctitis 1, diarrhea

                                                                                                              1, mucosal drainage 1

  3     36          right breast                                5130 (270)              yes                   fatigue 2, pain 3, dermatitis 1, hyperpigmentation 2

  4     18          pelvis and anus                             3000 (200)              yes                   dysuria 1

  5     82          prostate and SV                             6720 (320)              yes                   dysuria and nocturia and urinary frequency 2, anorexia 1, diarrhea 1, hematochezia 1

  6     18          prostate and SV                             8000 (200)              yes                   nocturia and urinary frequency 2

  7     7           prostate and SV                             7800 (200)              yes                   pain 1, dysuria and urinary frequency and incontinence 2, constipation 1, diarrhea 1

  8     8           left lateral chest wall                     3600 (300)              yes                   dermatitis 1

  9     38          brain                                       2000 (2000)             yes                   none

  10    25          head and neck                               7000 (200)              yes                   dermatitis 3, fatigue 3, dysphonia 1, xerostomia 2

  11    21          brain                                       3000 (300)              yes                   fatigue 2, pain 2, nausea 2, insomnia 2, anorexia 2, vomiting 2, ataxia 2

  12    23          right neck and left axilla                  3000 (200)              yes                   fatigue 1, pain 1, dermatitis 1, dysgeusia 1, dysphonia 1, xerostomia 1

  13a   147         right pelvis                                3000 (250)              yes                   fatigue 1

  13b   13          right axilla and ulcerating skin lesion     3060 (180)              yes                   dermatitis 2, drainage 3, pruritus 1

  13c   7           right temple and subcutaneous skin lesion   3060 (180)              yes                   dermatitis 2

  14    19          brain                                       3000 (300)              yes                   fatigue 1

  15    86          right breast                                6000 (200)              yes                   dermatitis 1

                                                                                                              fatigue 1, pain 2, nausea 1, nocturia and

  16    85          pelvis                                      5040 (180)              yes                   urinary frequency 1, anorexia 2, proctitis 1,

                                                                                                              diarrhea 2, dermatitis 2

  17    10          brain                                       3000 (300)              yes                   altered mental status in intensive care throughout treatment

  18    31          posterior scalp                             1600 (400)              yes                   none
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Patients are uniquely identified by numbers, repeated treatments on a patient are distinguished by a letter after the number.

F/U = follow-up

###### 

Radiation regimen, follow-up and toxicities in patients not receiving concurrent protease inhibitor

  \#   F/U \[weeks\]   Region treated               Dose (fractionation) \[cgy\]             Complete RT regimen   Acute toxicity and CTC grade
  ---- --------------- ---------------------------- ---------------------------------------- --------------------- ----------------------------------------------------------------------------
  1    6               Pelvis                       5400 (180)                               yes                   fatigue 1, nocturia 1, proctitis 2, gastrointestinal bleed 3, dermatitis 2
  2    6               vaginal cuff brachytherapy   4500 and 2500 HDR (180 and 500 HDR)      yes                   
  3    18              Abdomen                      5040 (180)                               yes                   fatigue 1, anorexia 1, nausea 1
  4    13              thoracic spine               3000 (300)                               yes                   fatigue 1
  5    29              Brain                        5400 (180)                               yes                   pain 2, edema 2
  6    44              prostate and SV              7800 (200)                               yes                   nocturia and urinary frequency and urgency 2, urinary retention 1
  7    20              Brain                        5300 (250 and 18 Gy gamma-knife boost)   yes                   memory impairment 1, concentration impairment 1
  8a   0               prostate and SV              7800 (200)                               yes                   dysuria and nocturia 2, urinary retention 1, constipation 1
  8b   13              Pelvis                       3780 and 1400 HDR (180 and 700 HDR)      no                    fatigue 2, anorexia 1, dermatitis 2
  8c   4               Pelvis                       3000 and 1200 IORT (200 and 1200 HDR)    yes                   fatigue 1, pain 1, nocturia 1, anorexia 1, proctitis 1, diarrhea 1
  9    13              Brain                        2400 (200)                               yes                   fatigue 2, pain 2,
  10   5               brain (repeated)             2400 (200)                               yes                   fatigue 2, anorexia 1, constipation 1, dermatitis 1,
  11   0               Testicles                    2700 (180)                               no, prescribed 4140   pain 1, constipation 1, dermatitis 1

Patients are uniquely identified by numbers, repeated treatments on a patient are distinguished by a letter after the number.

F/U = follow-up

HDR = high dose radiation

There were 64 acute toxicities in the group receiving PIs (30 grade 1, 30 grade 2, 4 grade 3). In the group not receiving PIs, there were 36 acute toxicities (23 grade 1, 13 grade 2). The median number of toxicities experienced per patient was not different between the groups (3 \[IQR 1-7\] with PIs; 3 \[IQR 2-3\] without PIs). Chi-square analysis of the distribution of severity did not find statistically significant difference in the severity of toxicities between the two groups (p = 0.38). One radiation treatment in each group was stopped early, but neither of these was secondary to toxicity (no grade 3 toxicities in either patient).

Discussion
==========

Our retrospective review of HIV-positive patients receiving radiation therapy found no increased toxicity in patients receiving concurrent PIs. The number and severity of toxicities experienced per patient were not found to be different in patients who were concurrently taking PIs compared to those who were not. There were differences in the baseline characteristics and medication regimens of the two groups. First, there were no cases of AIDS-defining malignancies in the group treated with PIs. This difference coincided with a difference in all HIV treatment and CD4 count. Significantly more patients in the non-PI group did not receive any medication to manage HIV, and significantly more patients in the non-PI group had CD4 counts below 500. This difference may reflect the efficacy of PIs and ART in controlling HIV, and a resulting decrease in opportunistic malignancies that has been observed with progressive generations of ART\[[@B9]\]. Although ART is typically initiated if the CD4 count is below 500, there are a number of other factors that contribute to the decision to initiate therapy, such as patient preference, adherence to prescriptions, and HIV strain. There was no association between CD4 count and adverse events.

There have been a number of case reports and small case series documenting seve re toxicities in HIV patients receiving radiation therapy. A meta-analysis of case reports and case series found severe toxicities in HIV patients receiving radiation therapy for Kaposi sarcoma and cervical carcinoma, but not in other malignancies\[[@B10]\]. Our results are in accordance with the only published study evaluating toxicities from interaction between PIs and radiation therapy \[[@B11]\]. Plastaras et al. reviewed 14 patients with concurrent PIs and 28 patients in the absence of PI, and found no difference in toxicity from radiation therapy. Although this group found no increase in toxicity from radiation therapy, the patient series was treated between 1993-2007 for the control group and 1997-2006 for the PI group. Inclusion of patients from this time period may have been reflected in the distribution of PIs and the distribution of malignancies treated. Nearly all patients in the Plastaras et al. study were treated with nelfinavir, three were treated with saquinavir (the oldest available PI), and one was treated with amprenavir (no longer available). 29 (69%) of 42 malignancies were AIDS-defining or strongly associated with HIV. These results may be limited by the baseline characteristics: AIDS-defining and HIV-associated malignancies are more heavily represented than in the current HIV+ population and PI regimens are evolving rapidly. Although not related to the years from which the patients were sampled, only 6 of the 14 patients from the PI group had documented CD4 count: one was \<50, two were \<200, and three \<500. No association was observed between CD4 count and radiation toxicity, but the data is limited.

Our study characterizes the safety of radiation therapy combined with the newer generation of PIs in treatment of non-AIDS defining malignancies which are increasingly common in the era of improved ART. The series included only patients treated from January 1, 2009 onwards: of the 18 patients receiving PIs, 16 (89%) were receiving a dual-PI regimen; only two were taking a mono-PI regimen (one ritonavir and one nelfinavir). The case series included more malignancies not associated with HIV or AIDS (ductal carcinoma of the breast, renal cell carcinoma, cholangiocarcinoma, and meningioma), and two non-malignancies (dural AVM, and keloid scar) that were treated with radiation. Half of the patients in this case series received definitive or adjuvant radiation dose regimens (45-78 Gy). These patients were distributed equally in the group with PIs and in the group without PIs, and combination of definitive/adjuvant doses of radiation with PIs did not increase toxicities over definitive/adjuvant radiation doses alone. The present study more than doubles the reported number of patients treated with HIV PIs and radiation from 14 to 32.

The limitations of this study include the small size, short follow-up, heterogeneous nature of our cohort, and the differences between the control group and the PI treatment group. As discussed before, in addition to not taking PI, the control group also received less non-PI HIV medications and had a lower median CD4 count. The factors that underlie these two differences may confound the results. In addition, although we collected data on late toxicities, there was insufficient follow-up (21 weeks \[IQR 10-38\] with PIs, 13 \[IQR 5-18\] without PIs) to assess differences in late toxicities. Extended follow-up is necessary to determine the impact on long term toxicities. In addition, the majority of the cases received ritonavir combined with a second PI. Ritonavir does not inhibit Akt, which is a proposed mechanism of radiosensitization by PIs \[[@B27]\]. However, there are no published studies evaluating the radiosensitizing effect of darunavir, atazanavir, or lopinavir, which were used in combination with ritonavir by the majority of the patients. Prior studies on radiosensitization by PIs have not found a defining structural characteristic which would predict whether a PI will increase radiosensitivity. In spite of these limitations, this retrospective review provides valuable information about the acute toxicity of combining radiation with current PI therapies. Review of this contemporary series of patients did not find an increase in acute toxicity from the combination of the newest generation of HIV PIs and radiation therapy to treat diverse pathologies.

Conclusions
===========

Preclinical data has suggested that PIs used in the treatment of HIV may radiosensitize cancer cells, but case reports have suggested that PIs may exacerbate radiotoxicity in normal tissue. Review of a set of HIV-positive radiation therapy patients did not reveal increased toxicity in patients taking PIs during radiation therapy. Our cohort doubles the number of patients in the current literature on the acute safety profile of combining PIs and radiation therapy. These data suggest that clinical trials of PIs as radiosensitizers will not encounter increased acute toxicity.
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